

Supporting information

Gadofullerene nanoparticles for robust treatment of aplastic anemia induced by chemotherapy

Wang Jia ^{a,b}, Mingming Zhen ^{a,b,*}, Lei Li ^{a,b}, Chen Zhou ^{a,b}, Zihao Sun ^{a,b}, Shuai Liu ^{a,b}, Zhongpu Zhao ^{a,b}, Jie Li ^{a,b}, Chunru Wang ^{a,b,*} and Chunli Bai ^{a,b,*}

a. Beijing National Laboratory for Molecular Sciences, Key Laboratory of Molecular Nanostructure and Nanotechnology, CAS Research/Education Center for Excellence in Molecular Sciences, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China.

b. University of Chinese Academy of Sciences, Beijing 100049, China.

Corresponding Email: zhenmm@iccas.ac.cn, crwang@iccas.ac.cn, clbai@cas.cn




Figure S1. The AFM of GFNPs.




Figure S2. The XPS data of GFNPs. (A) The XPS spectrum of GFNPs. **(B)** The relative atomic percent contents of C1s (1 C-C, C=C; 2 C-O; 3 C=O) of GFNPs.




Figure S3. The safety evaluations of GFNPs *in vivo*. (A) Schedule of animal experiment treated with GFNPs/NaCl. (B) The changes of body weight during 15 days after i.v. injection GFNPs/NaCl. (C) The changes of hematological indices of mice in different times. (D) The light Microscopy of H&E sections of heart, liver, spleen, lung, and kidney. Scale bars are 100 μ m.

Table S1. The blood analysis of hepatic and nephrotic toxicity of GFNPs. (n=5; * p < 0.05, ** p < 0.01, vs Control group)

Parameters	Groups		
	Control	AA	AA+GFNPs
ALT (U/L)	40.00 \pm 9.90	33.33 \pm 2.08	36.50 \pm 6.36
AST (U/L)	182.00 \pm 19.80	133.50 \pm 2.12*	199.00 \pm 9.92
ALP (U/L)	83.70 \pm 1.13	104.70 \pm 8.06*	92.75 \pm 8.27
UA (umol/L)	183.61 \pm 3.50	78.02 \pm 3.70**	122.39 \pm 29.31
BUN (mmol/L)	9.92 \pm 1.16	5.91 \pm 0.69*	6.98 \pm 0.64